Investor Overview

We are a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve the quality of patients' lives.

Using our proprietary sublingual spray technology and our capability to develop pharmaceutical cannabinoids, Insys addresses the clinical shortcomings of existing commercial products. Insys currently markets two products, Subsys®, which is sublingual Fentanyl spray for breakthrough cancer pain, and a generic version of Dronabinol (THC) capsules.

In March 2012, we launched Subsys® , our proprietary sublingual fentanyl spray for breakthrough cancer pain, or BTCP, in adult opioid-tolerant patients, through our cost-efficient commercial organization of approximately 250 sales professionals.

Since late 2014, Subsys® has been the most prescribed transmucosal immediate-release fentanyl, or TIRF, product with 48% market share on a prescription basis, according to IMS.

In December 2011, we launched Dronabinol SG Capsule, a generic equivalent to Marinol (dronabinol), an approved second-line treatment for chemotherapy-induced nausea and vomiting, or CINV, and anorexia associated with weight loss in patients with AIDS, through our exclusive distributor, a leading generic pharmaceutical company.

Our lead product candidate is Dronabinol Oral Solution, a proprietary orally administered liquid formulation of dronabinol, which would be our second branded supportive care product, if approved. We intend to market Dronabinol Oral Solution and any other future supportive care products, if approved, through our commercial organization.

Please see full prescribing information for Subsys® including the boxed warning.

 

Recent News

Aug 24 2016
Insys Therapeutics Reports Phase 3 Trial of Sublingual Buprenorphine Spray Met Primary Endpoint in Patients with Moderate-to-Severe Postoperative Pain after Bunionectomy
PHOENIX, Aug. 24, 2016 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ:INSY) ("Insys" or "the Company") today reported that the Phase 3 trial for the Buprenorphine Sublingual Spray met its primary endpoint.  The trial  was a multicenter, randomized, doub... 
Aug 18 2016
Insys Therapeutics Announces First Patient Enrolled in Phase II Trial for the Treatment of Cocaine Dependence Using Pharmaceutical Cannabidiol
PHOENIX, Aug. 18, 2016 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ:INSY) ("Insys" or "the Company") today announced enrollment of the first patient in a Phase II clinical trial for the treatment of cocaine dependence using its pharmaceutical cannabidi... 
Aug 03 2016
Insys Therapeutics Reports Second Quarter 2016 Results
PHOENIX, Aug. 03, 2016 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ:INSY) ("Insys" or "the Company") today announced financial results for the three-month period ended June 30, 2016. Highlights of and subsequent to the second quarter of 2016 include... 
see all news

Receive Email Alerts

Sign Up Now

Upcoming Events

There are currently no events scheduled.

see all events